⌘K

Tms (4891) · FactFirst stated

TMS-007 Clinical Trial Paper Ranks Highly for Publication and Views

First written in FY2026-H1. . Latest entry: FY2026-H1.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Academic Evaluation and Dissemination of Information on TMS-007 Clinical Trial PapersA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first

FY2026-H1First statedAnnual report
「A paper on the Phase I clinical trial of TMS-007 (JX10) was selected by Wiley in April 2025 as a “Top Viewed Article” among the most-viewed articles of 2023 in the international clinical pharmacology journal British Journal of Clinical Pharmacology. In addition, a paper on the early Phase II clinical trial results published in the journal Stroke, issued by the American Heart Association (AHA) and American Stroke Association (ASA), was featured in May 2025 on the journal’s information site, Blogging Stroke.」
The Company states that the TMS-007 Phase I paper was selected among the most-viewed articles, while the early Phase II results paper was featured on an academic information site.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

No upcoming earnings preview for Tms yet.

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.

TMS-007 Clinical Trial Paper Ranks Highly for Publication and Views | TMS Co.,Ltd. (4891) | Komori